title: Urological cancer. The benefits of intermittent androgen-deprivation therapy.
abstract: The large randomized study by Crook et al. demonstrated that intermittent administration of androgen deprivation therapy should be considered the standard of care when patients with moderate and well-differentiated localized prostate cancer are treated for rising PSA levels after definitive radiotherapy.
authors.affiliation: Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
authors.forename: Timur
authors.initials: T
authors.lastname: Mitin
authors.forename: Jason A
authors.initials: JA
authors.lastname: Efstathiou
authors.forename: William U
authors.initials: WU
authors.lastname: Shipley
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists